openPR Logo
Press release

NICOX discusses New Glaucoma Treatment at SMi’s 3rd Ophthalmic Drugs Conference

08-14-2019 03:52 PM CET | Health & Medicine

Press release from: SMi Group Ltd

NICOX discusses New Glaucoma Treatment at SMi’s 3rd

SMi Group Reports: NICOX recently announced that they have successfully tested a new treatment for the reduction of intraocular pressure in glaucoma. The NCX 470 Clinical Study went head-to-head on a daily dose of the treatment versus Latanoprost, which is perceived as the number one treatment for glaucoma and ocular hypertension.

Gavin Spencer who is Executive Vice President & Chief Business Officer, will be presenting at the third annual Ophthalmic Drugs Conference, where he will discuss the development of NCX 470. He will also focus on the role of nitric acid in control intraocular pressure and future generation compounds from the NICOX platform.

On Day Two of the conference, under the same discussion point on New Developments in Ophthalmic Clinical Trials and Drug Development, Parisa Zamiri, Global Head of Clinical Development in Ophthalmology at Novartis Pharmaceutical will discuss the transformation of future eye care and Virginia Calder, Reader in Ocular Immunology from UCL Institute of Ophthalmology highlights the use of experimental models to identify potential anti-inflammatory drugs in allergic conjunctivitis and uveitis.

Other high-profile speakers presenting include:
Aniz Girach, Chief Medical Officer, ProQR Therapeutics
Daniel Chung, Global Medical Strategy Lead-Ophthalmology, Spark Therapeutics
Michael Ehrlich, Senior Clinical Program Lead - Retinopathies, Boehringer Ingelheim
Peter Morgan-Warren, Medical Assessor, MHRA

Further details about the event can be found on the website

Sponsored by:

Sponsorship, exhibition and branding packages: Alia Malick +44 (0)20 7827 6168 /
Delegate enquiries: contact Alex Vidic on: +44 (0) 20 3866 0221 /

Media enquiries contact Neill Howard +44 (0) 207 827 6164 /

India House, 45 Curlew Street

Event Organisers

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release NICOX discusses New Glaucoma Treatment at SMi’s 3rd Ophthalmic Drugs Conference here

News-ID: 1822357 • Views: 486

More Releases from SMi Group Ltd

Patrick Clerens from ESWET to speak at Energy from Waste Conference 2019
SMi Reports: Patrick Clerens of ESWET has joined the speaker line up for the 12th annual Energy from Waste conference taking place on 3 - 4 December in London. SMi is pleased to welcome Patrick Clerens, Secretary General of ESWET to the list of esteemed speakers presenting at the Energy from Waste conference in London this December. This presentation follows an announcement from ESWET, the European Suppliers of
Digital Therapeutics Alliance speaker interview released for Disruptive Technolo …
SMi Reports: Jessica Shull from Digital Therapeutics Alliance to present at Disruptive Technologies in Pharma conference in London on the 20th and 21st January The highly anticipated launch of the inaugural Disruptive Technologies in Pharma conference is set to take place in London on 20th-21st January 2020. The conference will provide industry leaders with the unique opportunity to hear first-hand how the pharmaceutical industry is being shaped by developments in AI,
Regional CIS Experts to Present at Mobile Deployable Communications 2020
SMi Group Reports: Regional speakers will gather at the 13th Mobile Deployable Communications Conference in Warsaw, Poland on the 30th and 31st January 2020. The 13th annual Mobile Deployable Communications Conference will feature high class presentations by esteemed regional presenters from Poland, Romania, Lithuania and NATO. Register by Monday 30th September to save £400 with the early bird discount. Registrations can be made at: This annual military
An exclusive Aerie Pharmaceuticals speaker interview released for SMi’s Ophtha …
SMi Group Reports: Vice President of Aerie Pharmaceuticals to present at SMi’s Ophthalmic Drugs conference commencing on 18th- 20th November 2019 in London SMi catches up with Aerie Pharmaceuticals Vice President, Chemistry, Mitchell de Long as a speaker for the Ophthalmic Drugs conference taking place on the 18th- 20th November 2019 in London. As Europe’s leading Ophthalmic Drugs conference, the three-day agenda will explore new discoveries in the treatment of ocular

All 5 Releases

More Releases for NICOX

Artificial Tears Market Current and Future Demand 2025 with Top Manufactures All …
Global Artificial Tears Industry 2019 research report added by to its vast repository provides important statistics and analytical data to give a complete understanding of the market size, share, growth, trend, demand, top player, industry overview, opportunities, value cycle, end-users, technology, types and application. For Sample Copy of this Report @ Artificial tears are lubricant eye drops used to treat the dryness and irritation associated with deficient tear production in
Global Artificial Tears Market Analysis by Top Manufacturers: Johnson & Johnson, …
Qyresearchreports include new market research report Global Artificial Tears Market Research Report 2018 to its huge collection of research reports. In this report, the global Artificial Tears market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report is segmented into several key Regions, with production, consumption, revenue
Global Artificial Tears Market Trends, Share, Leading Players:Abbott, Wuhan Yuan …
The global market status for Artificial Tears Market is precisely examined through a smart research report added to the broad database managed by Market Research Hub (MRH). This study is titled “Global Artificial Tears Market” Insights, Forecast to 2025, which tends to deliver in-depth knowledge associated to the Artificial Tears Market market for the present and forecasted period until 2025. Furthermore, the report examines the target market based on market
Global Dry Eye Syndrome Treatment Market Professional Survey Report 2018: Novart …
Researchmoz added Most up-to-date research on "Global Dry Eye Syndrome Treatment Market Professional Survey Report 2018" to its huge collection of research reports. This report studies the global Dry Eye Syndrome Treatment market status and forecast, categorizes the global Dry Eye Syndrome Treatment market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and
Global Soluble Guanylate Cyclase Market Forecast 2018-2025 NicOx SA, Bayer AG, T …
A comprehensive market study on "Global Soluble Guanylate Cyclase Market 2018-2025" examines the performance of the Soluble Guanylate Cyclase market. It encloses an in-depth Research of the Soluble Guanylate Cyclase market state and the competitive landscape globally. This report analyzes the potential of Soluble Guanylate Cyclase market in the present and the future prospects from various angles in detail. Leading Manufacturers Analysis such as - Bayer AG, Boehringer Ingelheim GmbH, Ironwood
Blepharitis Market Key Players – Allergan Plc, InSite Vision Inc Merck & Co In …
Blepharitis Overview Blepharitis is an inflammation of the eyelids, usually caused by an excess growth of bacteria that is ordinarily found on the skin, blockage of the eyelid's oil glands, and occasionally allergies. Blepharitis signs and symptoms include watery eyes, red eyes, itchy eyelids, sensitivity to light. Treatment includes antibiotics, lubricating eye drops and steroid eye drops or ointments. Click here for sample report @   Major Key Players: Allergan Plc Hovione FarmaCiencia SA InSite Vision Inc Kala